Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6436 to 6450 of 7680 results

  1. Thrombophilia [ID393]

    Discontinued [GID-TAG374]

    Technology appraisal guidance
    Discontinued

  2. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued [GID-TAG278]

    Technology appraisal guidance
    Discontinued

  3. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued [GID-TAG507]

    Technology appraisal guidance
    Discontinued

  4. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued [GID-IP1041]

    Interventional procedures guidance
    Discontinued

  5. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued [GID-TAG387]

    Technology appraisal guidance
    Discontinued

  6. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued [GID-TAG382]

    Technology appraisal guidance
    Discontinued

  7. Pacritinib for treating myelofibrosis [ID880]

    Discontinued [GID-TA10133]

    Technology appraisal guidance
    Discontinued

  8. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    In development [GID-TA10598] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued [GID-TAG390]

    Technology appraisal guidance
    Discontinued

  10. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis [ID388]

    Discontinued [GID-TAG372]

    Technology appraisal guidance
    Discontinued

  11. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued [GID-TAG396]

    Technology appraisal guidance
    Discontinued

  12. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued [GID-TA10711]

    Technology appraisal guidance
    Discontinued

  13. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued [GID-NG10059]

    NICE guideline
    Discontinued

  14. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued [GID-TAG420]

    Technology appraisal guidance
    Discontinued

  15. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued [GID-TAG526]

    Technology appraisal guidance
    Discontinued